发布求助
文献互助 智能选刊 最新文献

Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
Lessons learned from the GAIA/CLL13 trial in chronic lymphocytic leukemia. 慢性淋巴细胞白血病GAIA/CLL13试验的经验教训
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-11-01
Moritz Fürstenau
{"title":"Lessons learned from the GAIA/CLL13 trial in chronic lymphocytic leukemia.","authors":"Moritz Fürstenau","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 8","pages":"472-474"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibody-drug conjugates in the treatment of lung cancer. 抗体-药物结合物治疗肺癌。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-11-01
Benjamin P Levy
{"title":"Antibody-drug conjugates in the treatment of lung cancer.","authors":"Benjamin P Levy","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 8","pages":"469-471"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of PSMA PET/CT imaging as an endpoint in clinical trials of prostate cancer. 使用PSMA PET/CT成像作为前列腺癌临床试验的终点
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-11-01
Michael J Morris
{"title":"The use of PSMA PET/CT imaging as an endpoint in clinical trials of prostate cancer.","authors":"Michael J Morris","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 8","pages":"475-477"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the potential of patient-reported outcomes: practical uses in routine oncology care. 释放患者报告结果的潜力：在常规肿瘤护理中的实际应用。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-11-01
Roshan Paudel, Nadine J McCleary, Michael J Hassett, Alicia K Morgans
{"title":"Unlocking the potential of patient-reported outcomes: practical uses in routine oncology care.","authors":"Roshan Paudel, Nadine J McCleary, Michael J Hassett, Alicia K Morgans","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A growing body of evidence supports the use of remote symptom monitoring based on patient-reported outcomes (PROs) to manage symptoms, improve quality of life, and reduce inpatient hospitalizations and emergency department visits. Health systems, payers, and specialty societies support the collection of PROs. Oncology practices are integrating PROs into their electronic health records to monitor and manage patients' health status and symptoms. Despite a growing evidence base and enthusiasm for the use of PROs, collection in routine oncology practice remains limited, with persistent gaps in our understanding of the value of PRO collection and practical methods of implementation. Ongoing research seeks to define methods to overcome these barriers and gaps. This review summarizes the practical uses and potential benefits of PROs in routine oncology care, discusses continued knowledge gaps, and highlights recent examples of successful implementation.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 8","pages":"512-519"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Converging approaches in the frontline treatment of mantle cell lymphoma. 套细胞淋巴瘤一线治疗的趋同方法。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-11-01
Dilan A Patel, Brad S Kahl
{"title":"Converging approaches in the frontline treatment of mantle cell lymphoma.","authors":"Dilan A Patel, Brad S Kahl","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mantle cell lymphoma is a biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that affects predominantly older patients. The disease remains incurable with modern therapies. The integration of first- and now second-generation Bruton tyrosine kinase inhibitors (BTKis) into earlier-line settings appears to improve outcomes. Remaining questions in the field relate to the need for chemotherapy and the choice and duration of maintenance therapy, given its cost and infectious complications. In this review, we highlight clinical data showing BTKis targeting genetic vulnerabilities within mantle cell lymphoma cells. We then assess the integration of these agents into the first-line setting for all patients with newly diagnosed disease. Special consideration is given to patients with TP53-mutated disease, for which non-chemotherapy approaches are preferred.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 8","pages":"497-507"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant therapy in melanoma: a new standard of care. 黑色素瘤的新辅助治疗：一种新的护理标准。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-10-01
Nikhil I Khushalani
{"title":"Neoadjuvant therapy in melanoma: a new standard of care.","authors":"Nikhil I Khushalani","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"423-426"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted immunotherapy in the treatment of childhood and adolescent mature B-cell lymphoma. 靶向免疫疗法治疗儿童和青少年成熟b细胞淋巴瘤。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-10-01
Anthony N Audino, Aliza Gardenswartz, Mitchell S Cairo
{"title":"Targeted immunotherapy in the treatment of childhood and adolescent mature B-cell lymphoma.","authors":"Anthony N Audino, Aliza Gardenswartz, Mitchell S Cairo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mature B-cell non-Hodgkin lymphomas (B-NHLs) comprise approximately 40% to 60% of all NHLs among children, adolescents, and young adults. Although overall survival with mature B-NHL approaches 90% in children younger than 15 years and 70% to 80% in adolescents and young adults, it is achieved with the use of intense therapeutic regimens, many of which lead to long-term effects that last for years after the patient's initial diagnosis and treatment. Chronic health issues, poor performance outcomes, impaired quality of life, and decreased fertility have all been associated with mature B-NHL therapy. As the role of targeted therapy in this population is elucidated, data continue to show that it can be incorporated safely into chemotherapy backbones, allowing a decrease in cytotoxic chemotherapy doses. These trends support ongoing efforts to find innovative combinatorial strategies that integrate new cell surface targets and use new classes of drugs, such as monoclonal antibodies, antibody-drug conjugates, checkpoint inhibitors, T-cell and natural killer-cell engagers, and chimeric antigen receptor T-cell therapy.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"436-445"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying FRESCO trial insights in real-world management of mCRC. 将FRESCO试验的见解应用于mCRC的实际管理。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-10-01
Farshid Dayyani
{"title":"Applying FRESCO trial insights in real-world management of mCRC.","authors":"Farshid Dayyani","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 Suppl 10 7","pages":"1-12"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting prostate-specific membrane antigen in prostate cancer. 靶向前列腺特异性膜抗原在前列腺癌中的作用。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-10-01
Louise Emmett
{"title":"Targeting prostate-specific membrane antigen in prostate cancer.","authors":"Louise Emmett","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"413-415"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of antibody-drug conjugates in gynecologic cancers. 抗体-药物偶联物在妇科癌症中的应用。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-10-01
Joyce F Liu
{"title":"The use of antibody-drug conjugates in gynecologic cancers.","authors":"Joyce F Liu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"410-412"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书